Jie Chen, Wenming Wu, Chunmei Bai, Yihebali Chi, Li Huo, Liming Jiang, Yuan Ji, Jie Luo, Jie Li, Jingnan Li, W. Lou, Chenghao Shao, Lin Shen, Feng Wang, Yu Wang, Ling Xue, Jin Xu, Chunhui Yuan, Xianjun Yu, Xiaoyu Yin, Hong Zhao, Xiongzeng Zhu, Yupei Zhao
{"title":"Consensus on the Clinical Diagnosis and Treatment of Grade 3 Pancreatic Neuroendocrine Tumors","authors":"Jie Chen, Wenming Wu, Chunmei Bai, Yihebali Chi, Li Huo, Liming Jiang, Yuan Ji, Jie Luo, Jie Li, Jingnan Li, W. Lou, Chenghao Shao, Lin Shen, Feng Wang, Yu Wang, Ling Xue, Jin Xu, Chunhui Yuan, Xianjun Yu, Xiaoyu Yin, Hong Zhao, Xiongzeng Zhu, Yupei Zhao","doi":"10.1097/jp9.0000000000000183","DOIUrl":null,"url":null,"abstract":"The World Health Organization (WHO) 2017 classifications for neuroendocrine neoplasms (NENs) subdivided grade 3 pancreatic neoplasms (pNENs) into G3 well-differentiated pancreatic neuroendocrine tumors (G3 pNETs) and poorly-differentiated pancreatic neuroendocrine carcinomas (pNECs), according to the mitotic count, Ki-67 index and cell differentiation. As a new category, G3 pNETs remains a challenging group of tumors to manage by lacking large randomized trials and consensus to support its clinical practice. Therefore, the Chinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association gathered experts in this field to formulate this consensus for the diagnosis and treatment of G3 pNETs.","PeriodicalId":92925,"journal":{"name":"Journal of pancreatology","volume":"14 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pancreatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/jp9.0000000000000183","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The World Health Organization (WHO) 2017 classifications for neuroendocrine neoplasms (NENs) subdivided grade 3 pancreatic neoplasms (pNENs) into G3 well-differentiated pancreatic neuroendocrine tumors (G3 pNETs) and poorly-differentiated pancreatic neuroendocrine carcinomas (pNECs), according to the mitotic count, Ki-67 index and cell differentiation. As a new category, G3 pNETs remains a challenging group of tumors to manage by lacking large randomized trials and consensus to support its clinical practice. Therefore, the Chinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association gathered experts in this field to formulate this consensus for the diagnosis and treatment of G3 pNETs.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
